Valle-Tamayo, N, Aranha, MR, Pérez-González, R, Serrano-Requena, S, Videla, L, Barroeta, I, Benejam, B, Chiva-Blanch, G, Jimenez, A, Busciglio, J, Wisniewski, T, Do Carmo, S, Alvarez-Sánchez, E, Muñoz, L, Bejanin, A, Belbin, O, Alcolea, D, Carmona-Iragui, M, Lleó, A, Cuello, AC, Fortea, J, Dols-Icardo, O, Iulita, MF. Nerve growth factor precursor alterations in neuron-derived extracellular vesicles from individuals with Down syndrome along the Alzheimer's disease continuum. ALZHEIMERS & DEMENTIA. 2025; 21(4)DOI:10.1002/alz.70137. PMID:40257051. IF:11.100(Q1/1D).

Ivain, P, Baksh, A, Saini, F, Idris, M, Tamayo-Elizalde, M, Wells, J, Benejam, B, Loosli, SV, Sandkühle, K, Wlasich, E, Wagemann, O, Levin, J, Martet, D, Sacco, S, Falquero, S, Clert, M, Rebillat, AS, Khoo, WM, Smith, MA, Beresford-Webb, J, Zaman, S, Carmona-Iragui, M, Videla, L, Fortea, J, Langballe, EM, Medboen, IT, Larsen, FK, Baldimtsi, E, Paradisi, R, Ntailakis, P, Tsolaki, M, Papantoniou, G, Mcglinchey, E, Mccarron, M, Kennelly, S, Strydom, A. Validation of the CAMCOG-DS-II, a neuropsychological test battery for Alzheimer's disease in people with Down syndrome: A Horizon 21 European Down syndrome Consortium study. ALZHEIMERS & DEMENTIA. 2025; 21(3)DOI:10.1002/alz.70071. PMID:40145416. IF:11.100(Q1/1D).

Koetsier, J, Cavill, R, Reijnders, R, Harvey, J, Homann, J, Kouhsar, M, Deckers, K, Kohler, S, Eijssen, LMT, van den Hove, DLA, Demuth, I, Düzel, S, Smith, RG, Smith, AR, Burrage, J, Walker, EM, Shireby, G, Hannon, E, Dempster, E, Frayling, T, Mill, J, Dobricic, V, Johannsen, P, Wittig, M, Franke, A, Vandenberghe, R, Schaeverbeke, J, Freund-Levi, Y, Frölich, L, Scheltens, P, Teunissen, CE, Frisoni, G, Blin, O, Richardson, JC, Bordet, R, Engelborghs, S, de Roeck, E, Martinez-Lage, P, Tainta, M, Lleó, A, Sala, I, Popp, J, Peyratout, G, Verhey, F, Tsolaki, M, Andreasson, U, Blennow, K, Zetterberg, H, Streffer, J, Vos, SJB, Lovestone, S, Visser, PJ, Lill, CM, Bertram, L, Lunnon, K, Pishva, E. Blood-based multivariate methylation risk score for cognitive impairment and dementia. ALZHEIMERS & DEMENTIA. 2024; 20(10)DOI:10.1002/alz.14061. PMID:39193899. IF:11.100(Q1/1D).

Huber, H, Montoliu-Gaya, L, Brum, WS, Vávra, J, Yakoub, Y, Weninger, H, Braun-Wohlfahrt, LS, Simrén, J, Boada, M, Ruiz, A, Cano, A, Orellana, A, Valero, S, Cañada, L, Tantinya, N, Nogales, AB, Sanz-Cartagena, P, Dittrich, A, Skoog, I, Sander-Long, M, Ballard, C, Richards, M, O'Leary, M, Clemmensen, FK, Wandall, HHD, Altomare, D, Cantoni, V, Stomrud, E, Palmqvist, S, Lleo, A, Alcolea, D, Iragui, MC, Hernandez, AS, Benejam, B, Toro, LV, Singh, A, Denkinger, MN, Simonsen, AH, Kern, S, Corbett, A, Fortea, J, Honigberg, L, Borroni, B, Hansson, O, Morató, X, Blennow, K, Zetterberg, H, Ashton, NJ. A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology. NATURE MEDICINE. 2026; 32(2)DOI:10.1038/s41591-025-04080-0. PMID:41491101. IF:50.000(Q1/1D).

Perera-Cruz, O, Solé-Padullés, C, Mulet-Pons, L, Cabello-Toscano, M, Morse, RM, Abellaneda-Pérez, K, Perellón-Alfonso, R, Cattaneo, G, Solana-Sánchez, J, Alviarez-Schulze, V, Bargalló, N, Fortea, J, Tormos, JM, Pascual-Leone, A, Zetterberg, H, Vaqué-Alcázar, L, Bartrés-Faz, D. Cortical mean diffusivity detects early age-related changes and associates with cognition and plasma biomarkers. Brain Communications. 2026; 8(1)DOI:10.1093/braincomms/fcaf511. PMID:41756214. IF:(Q/D).

André, C, Stankeviciute, L, Michaelian, JC, Antonsdottir, IM, Benca, RM, Coulthard, EJ, D'Rozario, AL, Dijk, DJ, Gimenez, S, Gorgoni, M, Leng, Y, Lucey, BP, Pase, MP, Rainey-Smith, SR, Rosenzweig, I, Spira, AP, Winer, JR, Rauchs, G, Naismith, SL. INTERNATIONAL RECOMMENDATIONS FOR SLEEP AND CIRCADIAN RESEARCH IN AGING AND ALZHEIMER'S DISEASE: A DELPHI CONSENSUS STUDY. SLEEP MEDICINE. 2026; 138DOI:. PMID:. IF:3.400(Q2/3D).